Get started
Author

Patricia Bourguignon

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
2011 · Sandra Morel, Arnaud Didierlaurent, et al. · Vaccine · 480
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
2017 · Margherita Coccia, Catherine Collignon, et al. · npj Vaccines · 265
PDF
Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
2014 · Arnaud M Didierlaurent, Catherine Collignon, et al. · The Journal of Immunology · 265
Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults
2013 · Cheryl L. Day, Michele Tameris, et al. · American Journal of Respiratory and Critical Care Medicine · 119
Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen
2008 · Pascal Mettens, Patrice M. Dubois, et al. · Vaccine · 79
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems
2010 · Isabel Leroux-Roels, Marguerite Koutsoukos, et al. · Vaccine · 76
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
2020 · Milagritos D Tapia, Samba O Sow, et al. · The Lancet Infectious Diseases · 71
PDF
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
2020 · Milagritos D Tapia, Samba O Sow, et al. · The Lancet Infectious Diseases · 62
An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers
2011 · Eva Van Braeckel, Patricia Bourguignon, et al. · Clinical Infectious Diseases · 62
PDF
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
2021 · Sonia Budroni, Francesca Buricchi, et al. · npj Vaccines · 58
PDF
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults
2015 · Gloria Omosa-Manyonyi, Juliet Mpendo, et al. · PLoS ONE · 35
PDF
Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques
2012 · Clarisse Lorin, Lawrence Segal, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 29
PDF
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study
2013 · Thomas Harrer, Andreas Plettenberg, et al. · Vaccine · 28
Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients
2014 · Patricia Bourguignon, Frédéric Clément, et al. · Journal of Immunological Methods · 25
Induction of Strong HIV-1–Specific CD4+ T-Cell Responses Using an HIV-1 gp120/NefTat Vaccine Adjuvanted With AS02A in Antiretroviral-Treated HIV-1–Infected Individuals
2011 · Mathias Lichterfeld, Rajesh T. Gandhi, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 20
Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine
2014 · Geert Leroux-Roels, Patricia Bourguignon, et al. · Clinical and Vaccine Immunology · 15
PDF
Vaccine-induced HIV seropositivity: A problem on the rise
2011 · Eva Van Braeckel, Marguerite Koutsoukos, et al. · Journal of Clinical Virology · 15
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial
2016 · Ying Huang, Carlos DiazGranados, et al. · Current Opinion in Virology · 14
PDF
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults
2016 · Warren Dinges, Pierre-Marie Girard, et al. · Medicine · 9
Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
2018 · Margherita Coccia, Catherine Collignon, et al. · npj Vaccines · 5
PDF
Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines+/− Adjuvanted Protein or Electroporated DNA
2014 · Peter Hayes, Natalia Fernandez, et al. · AIDS Research and Human Retroviruses
Co-administration of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef (Ad35-GRIN) is well tolerated and induces potent, polyfunctional CD4+ and CD8+ T cell responses.
2013 · Patricia Bourguignon, Roman François, et al.
Works count: 23
Citation count: 1,732
H-index: 15
I10-index: 18
Year
Topic
Type